Results 261 to 270 of about 378,224 (340)

Evaluating Sex Disparity in Pancreatic Ductal Adenocarcinoma Risk in the UK Biobank Cohort

open access: yesUnited European Gastroenterology Journal, EarlyView.
ABSTRACT Background The incidence of pancreatic ductal adenocarcinoma (PDAC) is lower in females than males (19.0 vs. 20.2 for 100,000 individuals in Europe). This disparity is commonly attributed to differences in exposure to lifestyle risk factors such as smoking and alcohol consumption; however, hormonal activity may also play a role. Objective This
Giulia Peduzzi   +6 more
wiley   +1 more source

Unveiling the potential of emerging microRNA panels as diagnostic biomarkers for prostate cancer: A review

open access: yesUroPrecision, EarlyView.
Abstract Prostate cancer (PCa) is a multifaceted disease that envelops 1.41 million new cases globally. It is the second most common cancer reported in men. Its heterogeneity and indolent growth, coupled with incompetent early screening methods such as serum prostate‐specific antigen level estimations and digital rectal examinations, contribute to its ...
Anveshika Manoj   +2 more
wiley   +1 more source

Development of a prognostic nomogram and genetic insights for prostate cancer patients with secondary primary malignancies: A SEER retrospective cohort study and Mendelian randomization analysis

open access: yesUroPrecision, EarlyView.
Abstract Background Prostate cancer (PCa) patients are at risk of developing second primary malignancies (SPMs), which can significantly shorten their survival. Understanding the risk of SPMs and associated factors is crucial to the optimization of patient follow‐up.
Qi Zhang   +11 more
wiley   +1 more source

Organoid‐based novel technology for antitumor drug screening

open access: yesVIEW, EarlyView.
Organoids represent a cutting‐edge research model that closely mimics in vivo organ physiology, making them highly valuable for tumor immunotherapy drug screening. This review explores the integration of organoids with advanced technologies, such as gene editing, 3D bioprinting, and AI, highlighting novel fusion platforms and their applications.
Yu Su   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy